Cellectis S.A. (CLLS)
NASDAQ: CLLS · IEX Real-Time Price · USD
2.900
+0.330 (12.84%)
May 2, 2024, 2:15 PM EDT - Market open
Cellectis Revenue
In the year 2023, Cellectis had annual revenue of $9.19M, a decrease of -64.26%. Revenue in the quarter ending December 31, 2023 was $1.99M, a -88.51% decrease year-over-year.
Revenue (ttm)
$9.19M
Revenue Growth
-64.26%
P/S Ratio
21.39
Revenue / Employee
$39,797
Employees
231
Market Cap
205.44M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.73M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
Dec 31, 2018 | 21.43M | -12.28M | -36.43% |
Dec 31, 2017 | 33.72M | -22.73M | -40.27% |
Dec 31, 2016 | 56.44M | -6.12M | -9.78% |
Dec 31, 2015 | 62.57M | 31.43M | 100.95% |
Dec 31, 2014 | 31.14M | 16.16M | 107.90% |
Dec 31, 2013 | 14.98M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Rigel Pharmaceuticals | 116.88M |
OptimizeRx | 71.52M |
Innate Pharma | 68.49M |
Semler Scientific | 68.18M |
908 Devices | 50.23M |
MediWound | 18.69M |
Profound Medical | 5.41M |
CLLS News
- 2 days ago - Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 - GlobeNewsWire
- 9 days ago - Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs - GlobeNewsWire
- 21 days ago - Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs - GlobeNewsWire
- 23 days ago - Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting - GlobeNewsWire
- 3 months ago - Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB) - GlobeNewsWire
- 4 months ago - Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 - GlobeNewsWire
- 5 months ago - Cellectis' Shareholders Meeting to be Held on December 22, 2023 - GlobeNewsWire
- 6 months ago - Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca - GlobeNewsWire